Colonoscopy evaluation after short-term anti-tuberculosis treatment in nonspecific ulcers on the ileocecal area

Table 1 Clinical characteristics

Group	Tbc colitis (n = 7 )	Nonspecific ulcers (n =18)		P1
		Suspicious tbc colitis (n = 9 )	Suspicious IBD (n = 9 )
M/F	4/3	2/7	4/5	NS
Median age (yr)	40.1	44.1	28.1	0.03
Chest X-ray (%)
Active pulmonary tbc	5 (71.4)	3 (33.3)	0 (0)
Old pulmonary tbc	0 (0)	2 (22.2)	0 (0)	< 0.001
Normal	2 (28.6)	4 (44.4)	9 (100)
Lab finding (%)
ESR rise	7 (100)	8 (88.9)	9 (100)	NS
pANCA (+/-)	Not check	Not check	1/8 (11.1/88.9)
Small bowel lesion (%)
No lesion	4 (57.1)	4 (44.4)	3 (33.3)
Jejunum	0 (0)	0 (0)	0 (0)
Prox. ileum	0 (0)	0 (0)	1 (11.1)	NS
Terminal ileum	3 (42.9)	5 (55.5)	6 (66.7)
Anal & rectal lesion (%)	0 (0)	0 (0)	0 (0)

NS: Not significant.

¹Significant at P < 0.05 by Fisher’s exact test and Kruskall-Wallis test.

Table 2 Colonoscopy features before anti-tuberculosis medication trial

Group	Tbc colitis (n = 7 )	Nonspecific ulcers ( n = 18)		P1
		Suspicious tbc colitis (n = 9 )	Suspicious IBD (n = 9 )
Location of lesion (%)
Terminal ileum	3 (42.9)	5 (55.6)	6 (66.7)	NS
IC valve	5 (71.4)	8 (88.9)	7 (77.8)	NS
Cecum	2 (28.6)	2 (22.2)	5 (55.6)	NS
Prox. Ascending colon	6 (85.7)	6 (66.7)	6 (66.7)	NS
Shape of lesion
Geographic ulcer	3 (42.9)	2 (22.2)	2 (22.2)	NS
Irregular ulcer	1 (14.3)	3 (33.3)	5 (55.6)	NS
Aphthous ulcer	0 (0)	2 (22.2)	6 (66.7)	0.01
Transverse ulcer	3 (42.6)	2 (22.2)	2 (22.2)	NS
Stenosis	2 (28.6)	1 (11.1)	2 (22.2)	NS
Pathology (%)
Granuloma	2 (28.6)	3 (28.0)	4 (44.4)	NS
Caseating granuloma	4 (57.1)	0 (0)	0 (0)	0.01
Acid fast bacilli+	3 (21.7)	0 (0)	0 (0)	0.01
Non-specific inflammation	0 (0)	6 (66.7)	5 (55.6)	0.02

NS: Not significant.

¹Significant at P < 0.05 by Fisher’s exact test.

Table 3 Follow-up colonoscopy results and feasibility to anti-tuberculosis

Group	Tbc colitis (n = 7 )	Nonspecific ulcers ( n = 18)		P1
		Suspicious tbc colitis (n = 9 )	Suspicious IBD (n = 9 )
Active ulcer	0/7	0/9	9/9	< 0.001
Improvement of stenosis	2/2	0/1	0/2	NS
No. of inflammatory polyps	Increase	Increase	Increase	NS
Extent of lesion	Decrease	Decrease	Increase	0.01
Feasibility to drug (%)				0.01
Very good	5 (71.4)	4 (44.4)	0 (0)
Good	2 (28.6)	5 (55.6)	5 (55.6)
Poor	0 (0)	0 (0)	4 (44.4)

NS: Not significant.

¹Significant at P < 0.05 by Fisher’s exact test.

Table 4 Final diagnosis of the patients of “suspicious inflammatory bowel disease group”

Patient	Response	Other manifestation during follow-up	Final Dx
#1 F/32	Response to mesalazine		CD
#2 F/15	Response to steroid	perianal abscess after 2 years	CD
#3 F/20	Response to mesalazine		CD
#4 F/39	No response to mesalazine, active ulcer and symptoms	hemicolectomy	Non-specific ulcers
#5 M/24	Response to mesalazine		CD
#6 M/42	Response to steroid		CD
#7 M/16	Response to mesalazine	Ileocecectomy due to ileal perforation after 2 years	CD
#8 F/27	Response to mesalazine	perianal fistula after 2 years	CD
#9 M/26	Response to steroid	perianal abscess after 1 year	CD